Life Sciences Venture Fund aMoon Nearing Cap of Second Fund, Says Co-Founder

Life Sciences Venture Fund aMoon Nearing Cap of Second Fund, Says Co-Founder

The Israel-based firm announced in April it is raising a second, $500 million fund with a hard cap of $750 million. Credit Suisse is a major investor

Lilach Baumer  :  2018-11-08T13:06:16..
Israel-based life sciences, healthcare, and technology venture capital firm aMoon has passed its $500 million target for its second fund and is close to its hard cap of $750 million, co-founder Yair Schindel announced in a LinkedIn post Wednesday.

Founded in 2016 by Schindel, the former CEO of Israel’s National Digital Bureau, and Marius Nacht, the co-founder of firewall pioneer Check Point Software Technologies Ltd., aMoon's first fund was backed exclusively by Nacht. In April, the firm launched a second fund to focus on mid to late-stage health companies in the domains of pharma, digital health, and medical technology. Credit Suisse AG committed $250 million to the fund in May.

In his post, Schindel said the fund has secured commitments from over 50 investors, adding that aMoon expects their number to reach between 70 and 80 by the time the fund closes in December.

Healthcare (illustration). Photo: Shutterstock Healthcare (illustration). Photo: Shutterstock Healthcare (illustration). Photo: Shutterstock

share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS